Skip to main content
OpenTrials
Completed

NCT Number: NCT00440661

Exploration of the Synovial Fluid Inflammation Mediators Under Diacerhein in Knee Osteoarthritis

Some inflammation mediators, notably IL-1, are implied in the joint degeneration phenomena of osteoarthritis. The aim of this study is to confirm in vivo the favourable effect of diacerhein on IL-1 and also to appreciate its effect on other synovial inflammation mediators.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases

Age range

45 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Rheumatologic Institut of Montreal

Montreal, Quebec, H2L1S6, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Painful osteoarthritis
  • Hydarthrosis (synovial effusion)

Exclusion criteria

  • large effusion
  • severe pathologies
  • anti-osteoarthritic treatments

Treatment and study plan

Diacerhein

Drug

Primary outcomes

  1. Synovial concentration of IL-1

Secondary outcomes

  1. Synovial concentration of IL-6

  2. WOMAC

Sponsors and collaborators

Lead sponsor

Laboratoires NEGMA

Industry

Registry information

Official study title

Exploratory Study of Some Synovial Fluid Inflammation Mediatorsunder Diacerhein in Knee Osteoarthritis Patients. Phase IV Study.

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Feb 27, 2007
Registry last updated
Mar 4, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.